Vinblastine SulphateThird Party Manufacturing in India

Vinblastine is a vinca alkaloid that disrupts cell division by interfering with microtubule dynamics. Microtubules are structural components of the cytoskeleton that form the mitotic spindle during cell division, allowing proper chromosome segregation. Vinblastine binds with high affinity to tubulin, the protein subunit that polymerizes to form microtubules, and prevents its assembly into functional microtubules. Without a functional mitotic spindle, dividing cells are arrested in metaphase and cannot complete mitosis. This arrested state ultimately triggers programmed cell death through apoptosis. Vinblastine is cell cycle-specific, acting primarily during the M-phase of the cell cycle. It is extracted from the Madagascar periwinkle plant, Catharanthus roseus, and is one of several clinically important vinca alkaloids derived from this source. Unlike many other chemotherapeutic agents, vinblastine causes relatively mild bone marrow suppression at standard therapeutic doses, making it valuable in combination regimens. The drug also exhibits some immunosuppressive activity and can interfere with glutamic acid metabolism and nucleic acid biosynthesis at higher concentrations, contributing to its overall antineoplastic effect.

Therapeutic Uses

Vinblastine Sulphate is prescribed for the treatment of:

• Hodgkin Lymphoma: A key component of the ABVD regimen, one of the most effective standard treatments for advanced Hodgkin lymphoma.
• Non-Hodgkin Lymphoma: Used in various combination chemotherapy protocols for aggressive NHL subtypes.
• Testicular Cancer: Effective against advanced testicular germ cell tumors as part of platinum-based combination regimens.
• Kaposi Sarcoma: Used in AIDS-related and classic Kaposi sarcoma, particularly for mucocutaneous disease.
• Breast Cancer: Used as palliative therapy in advanced breast cancer that has progressed after other treatments.
• Choriocarcinoma: Used in gestational trophoblastic disease that has not responded to other chemotherapy.

Why Manufacturers Choose Vinblastine Sulphate

Vinblastine Sulphate is a well-established oncology molecule with over six decades of clinical use. Indian manufacturers benefit from the molecule being off-patent, allowing cost-effective generic production without licensing barriers. Both lyophilized and liquid injectable forms are in demand across hospital and PCD franchise channels. The lyophilized form is preferred for its extended shelf life and stability, while the liquid injection offers convenience for clinical use. Vinblastine is consistently included in standard lymphoma chemotherapy regimens, ensuring steady institutional demand. WHO-GMP certification is essential for manufacturers targeting regulated export markets.